We have a robust pipeline of therapeutic development programs to address several clinical IBD patient subpopulations, and plan to develop a companion diagnostic for each program.
|PRA023 - Anti-TL1A mAb for UC and CD|
|PR600 - Anti-TNF Super Family Member mAb for IBD|
|PR300 - GPCR Modulator Small Molecule for IBD|
Prometheus has an early-stage discovery collaboration with Takeda Pharmaceuticals.